Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Jan 1;99(1-3):222-30.
doi: 10.1016/j.drugalcdep.2008.08.006. Epub 2008 Oct 18.

Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial

Stephen Magura  1 , Joshua D Lee, Jason Hershberger, Herman Joseph, Lisa Marsch, Carol Shropshire, Andrew Rosenblum
Affiliations
Randomized Controlled Trial

Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial

Stephen Magura et al. Drug Alcohol Depend. .

Abstract

Buprenorphine has rarely been administered as an opioid agonist maintenance therapy in a correctional setting. This study introduced buprenorphine maintenance in a large urban jail, Rikers Island in New York City. Heroin-dependent men not enrolled in community methadone treatment and sentenced to 10-90 days in jail (N=116) were voluntarily randomly assigned either to buprenorphine or methadone maintenance, the latter being the standard of care for eligible inmates at Rikers. Buprenorphine and methadone maintenance completion rates in jail were equally high, but the buprenorphine group reported for their designated post-release treatment in the community significantly more often than did the methadone group (48% vs. 14%, p<.001). Consistent with this result, prior to release from Rikers, buprenorphine patients stated an intention to continue treatment after release more often than did methadone patients (93% vs. 44%, p<.001). Buprenorphine patients were also less likely than methadone patients to withdraw voluntarily from medication while in jail (3% vs. 16%, p<.05). There were no post-release differences between the buprenorphine and methadone groups in self-reported relapse to illicit opioid use, self-reported re-arrests, self-reported severity of crime or re-incarceration in jail. After initiating opioid agonist treatment in jail, continuing buprenorphine maintenance in the community appears to be more acceptable to offenders than continuing methadone maintenance.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CONSORT diagram for RAMS
See this image and copyright information in PMC

References

    1. Administrative Office of U.S. Courts. The Guide to Judiciary Policies and Procedures: Probation Manual Vol. 10. Government Printing Office; Washington, DC: 1994.
    1. Alho H, Sinclair D, Vuori E, Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend. 2007;88:75–8. - PubMed
    1. Amass L, Kamien JB, Mikulich SK. Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet. Drug Alcohol Depend. 2000;58:143–52. - PubMed
    1. Amon JJ, Garfein RS, Ahdieh-Grant L, Armstrong GL, Ouellet LJ, Latka MH, Vlahov D, Strathdee SA, Hudson SM, Kerndt P, Des Jarlais D, Williams IT. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin Infect Dis. 2008;46:1852–8. - PubMed
    1. Anglin MD, Perrochet B. Drug use and crime: A historical review of research conducted by the UCLA Drug Abuse Research Center. Substance Use and Misuse. 1998;33:1871–1914. - PubMed

Publication types

MeSH terms